Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 95

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 3
Chunk 95
---
As a smaller reporting company, as defined by
Item 10(f)(1) of Regulation S-K, we are not required to provide the information required by this item.

 27 

ITEM 4. CONTROLS AND PROCEDURES.

DISCLOSURE CONTROLS AND PROCEDURES

We maintain “disclosure controls and procedures”
(as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed,
in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules
and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief
Financial Officer (who is our principal executive officer and principal financial officer), to allow timely decisions regarding required
disclosures.

Under the supervision
and with the participation of our management, including our Chief Executive Officer, who also serves as our Chief Financial Officer, we
evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)
of the Exchange Act) as of the end of the period covered by this Quarterly Report.

Based on such evaluation,
our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures
are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the
reports that we file or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in
the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive
Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As previously reported in our Annual Report on
Form 10-K for the year ended March 31, 2024, we identified a material weakness in our internal control over financial reporting related
to segregation of duties within our financial systems. Specifically, user access controls were not sufficiently maintained to properly
restrict both user and privileged access to financial applications within our accounting software system to initiate, record and approve
entries. Also noted that check stock was secured in an authorized signatory’s office.

Since identifying the material weakness, we have
been actively engaged in implementing measures to remediate the weakness and enhance our internal control over financial reporting. These